ArticleMolecular psychiatry2021
Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms.
Open access · bronzeAbstract readLetterComment
In one paragraph
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Pooled it
- Immune response to vaccination in adults with mental disorders: A systematic review.Journal of affective disorders · 2022Pooled it
- The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis.Molecular psychiatry · 2026Review
- The role of peripheral serotonin in SARS-CoV-2 infectivity, COVID-19 treatment and long COVID.Immunology and cell biology · 2026Review
- Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Serotonin deficiency and psychiatric long COVID: both caused specifically by the virus itself or an adaptive general stress response?European archives of psychiatry and clinical neuroscience · 2025Article
- Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Physical and cognitive correlates, inflammatory levels, and treatment response in post-COVID-19 first-onset vs. recurrent depressive episodes.European archives of psychiatry and clinical neuroscience · 2024Article
- Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.EClinicalMedicine · 2024Article
- Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.Viruses · 2024Article
- Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases.Frontiers in medicine · 2024Article
- Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study.Molecular psychiatry · 2023Article
- Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents.Microorganisms · 2023Review
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal transduction and targeted therapy · 2023Review
- Effects of Antidepressants on COVID-19 Outcomes: Retrospective Study on Large-Scale Electronic Health Record Data.Interactive journal of medical research · 2023Article
- Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania.Molecular psychiatry · 2023Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
12 authors at 7 institutions in 4 countries.
Nicolas HoertelDMU Psychiatrie et Addictologie, Département de Psychiatrie, Assistance Publique-Hôpitaux de Paris, Hôpital Corentin-Celton,INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, Paris, France. nico.hoertel@yahoo.fr.ORCID http://orcid.org/0000-0002-7890-1349
Marina Sánchez-RicoDMU Psychiatrie et Addictologie, Département de Psychiatrie, Assistance Publique-Hôpitaux de Paris, Hôpital Corentin-Celton,INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, Paris, France.ORCID http://orcid.org/0000-0002-1121-8641
Céline CougouleInstitut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, Toulouse, France.
Erich GulbinsInstitute of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-8096-3987
Alexander CarpinteiroInstitute of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
Katrin Anne BeckerInstitute of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
Angela M ReiersenDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-3203-4590
Eric J LenzeDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
David SeftelGolden Gate Fields Medical Clinic, Berkeley, CA, USA.
Cédric LemogneUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.ORCID http://orcid.org/0000-0002-3487-4721
Frédéric LimosinDMU Psychiatrie et Addictologie, Département de Psychiatrie, Assistance Publique-Hôpitaux de Paris, Hôpital Corentin-Celton,INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, Paris, France.
Inserm · FRInstitute of Molecular Biology · DEWashington University in St. Louis · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGolden Gate University · USUniversidad Complutense de Madrid · ESUniversité Fédérale de Toulouse Midi-Pyrénées · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Sphingomyelin PhosphodiesteraseAntidepressive AgentsCeramidesHumansPrescriptionsRimonabantSARS-CoV-2Antidepressive AgentsCeramidesRimonabantSphingomyelin Phosphodiesterase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.